Phaseline

Targets › FKBP1A

FKBP1A (Peptidyl-prolyl cis-trans isomerase FKBP1A): drug programs, companies and trials

17 programs from 16 companies in 194 trials: 103 Phase 2, 45 Phase 1, 27 Phase 3, 19 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.

Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. (UniProt, P62942)

Open in Phaseline: the race on FKBP1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Novartiseverolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 4Renal Angiomyolipoma; Tuberous Sclerosis Complex; Advanced Breast Cancer; Renal Cell Carcinoma …Dec 2026
University Hospital, LimogesLCP-tacrolimus
Calcineurin inhibitor
FKBP1APhase 4Liver TransplantationApr 2028
University Hospital, LimogesXR-tacrolimus
Calcineurin inhibitor
FKBP1APhase 4Liver TransplantationApr 2028
EisaiEverolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Renal Cell CarcinomaMar 2027
Palvella TherapeuticsSirolimus (PTX-022)
FK506-binding protein 1A inhibitor
FKBP1APhase 3Pachyonychia Congenita; Cutaneous Venous Malformations; AngiokeratomasAug 2027
Mercator MedSystemsTemsirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Peripheral Artery Disease; Alveolar Rhabdomyosarcoma; Advanced Rare Tumours; Endometrial Adenocarcinoma …Feb 2028
Université de SherbrookeCBD Oral Solution
FK506-binding protein 1A inhibitor
FKBP1A, PTGS2, IL4RPhase 3Asthma Control; Organ Transplant Failure or Rejection; Fragile X Syndrome; Triple-Negative Breast CancerJul 2028
Jiangsu Simcere PharmaceuticalEverolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Locally Advanced or Metastatic Breast CancerAug 2028
Rapamycin HoldingsSirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Familial Adenomatous Polyposis (FAP); Familial Adenomatous PolyposisJul 2030
AgelessRxSirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Healthspan Improvement; Longevity–
Aadi BioscienceSirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 2Tumor; Endometrial Cancer; Tumor, SolidDec 2026
CSPC ZhongQi Pharmaceutical TechnologySirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 2HR+/HER2- Advanced/Metastatic Breast Cancer; Gastroenteropancreatic Neuroendocrine Tumors; Advanced Solid Tumors; Antiphospholipid (aPL)-Positive …Oct 2027
RestorbioEverolimus (RAD001)
FK506-binding protein 1A inhibitor
FKBP1APhase 2Respiratory Tract Infections–
NovaliqTacrolimus (NOV05)
FK506-binding protein 1A inhibitor
FKBP1APhase 2Non-infectious Anterior Uveitis; Kidney Transplantation; Kidney Disease, End-Stage; Renal Transplant Recipients …–
Eyestem ResearchTacrolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 1Retinal DiseaseDec 2030

Conditions

Aging (6) Sickle Cell Disease (6) Breast Cancer (5) Tuberous Sclerosis Complex (4) Advanced Cancer (4) Liver Transplantation (3) Renal Cell Carcinoma (2) Systemic Lupus Erythematosus (2) Vascular Malformations (2) Lymphatic Malformation (2) Genetic Predisposition to Disease (2) Multiple Myeloma (2)

Modalities

small molecule (14), mixed (2), protein or peptide (1)

Companies

University Hospital, Limoges (2) Eisai (1) CSPC ZhongQi Pharmaceutical Technology (1) Restorbio (1) Novartis (1) Université de Sherbrooke (1) Rapamycin Holdings (1) AgelessRx (1) Novaliq (1) Palvella Therapeutics (1) Jiangsu Simcere Pharmaceutical (1) Aadi Bioscience (1) Odense University Hospital (1) University of Pennsylvania (1) Eyestem Research (1) Mercator MedSystems (1)

Related targets

TNF (2) PTGS2 (1) IL4R (1) GLP1R (1) ATP4A (1) ATP4B (1) CTLA4 (1) PDCD1 (1) SCNN1A (1) SCNN1B (1) SCNN1G (1) CHRNA4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.